Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
O15533
UPID:
TPSN_HUMAN
Alternative names:
NGS-17; TAP-associated protein; TAP-binding protein
Alternative UPACC:
O15533; A2AB91; A2ABC0; B0V003; B0V0A6; B2ZUA4; E9PGM2; O15210; O15272; Q5STJ8; Q5STK6; Q5STQ5; Q5STQ6; Q66K65; Q96KK7; Q9HAN8; Q9UEE0; Q9UEE4; Q9UIZ6; Q9Y6K2
Background:
Tapasin, also known as NGS-17 or TAP-binding protein, plays a crucial role in immune response. It facilitates the association of MHC class I molecules with the transporter associated with antigen processing (TAP) and assists in the assembly of MHC class I with peptides, a process vital for antigen presentation.
Therapeutic significance:
Tapasin's involvement in Bare Lymphocyte Syndrome 1, characterized by chronic respiratory infections due to HLA class I deficiency, underscores its therapeutic potential. Enhancing Tapasin function could offer new strategies for treating this immune disorder.